We are live on !
Find out more
Stempoint Capital Portfolio holdings
AUM
$560M
Turnover
64.34%
1-Year Est. Return
146.87%
This Fund
S&P 500
This Quarter Est. Return
+5.16%
1 Year Est. Return
+146.87%
3 Year Est. Return
+725.67%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$401M
AUM Growth
+$66.6M
(+20%)
Cap. Flow
+$95.5M
Cap. Flow % of AUM
Cap. Flow %
23.85%
Top 10 Holdings %
Top 10 Hldgs %
50.8%
Holding
80
New
26
Increased
21
Reduced
6
Closed
26
Avg Time Held
Equity + Options
0.3
years
Top 10 Avg Time Held
Equity + Options
0.4
years
Top 20 Avg Time Held
Equity + Options
0.3
years
Avg Time Held Equity only
0.3
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Syndax Pharmaceuticals
SNDX
|
+$19.5M |
| 2 |
Xenon Pharmaceuticals
XENE
|
+$15.5M |
| 3 |
Nuvalent
NUVL
|
+$13.6M |
| 4 |
Immunovant
IMVT
|
+$12.7M |
| 5 |
Alkermes
ALKS
|
+$10.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amicus Therapeutics
FOLD
|
+$15.8M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
+$14M |
| 3 |
Applied Therapeutics
APLT
|
+$13.2M |
| 4 |
Autolus Therapeutics
AUTL
|
+$9.5M |
| 5 |
Day One Biopharmaceuticals
DAWN
|
+$7.06M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.15% |
| 2 | Miscellaneous | 0.46% |
| 3 | Financials | 0.38% |
Similar funds
AAM
MHR
Stempoint Capital's Q4 2024 Portfolio in Review
As of Q4 2024, Stempoint Capital held 80 positions worth $401M, up 20% from $334M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Stempoint Capital deployed $95.5M of net new capital in Q4 2024, opening 26 new positions and adding to 21 existing holdings. Its largest new stake was Xenon Pharmaceuticals: 375,845 shares worth $14.7M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Arcutis Biotherapeutics, an estimated $14M trimmed.
- Stempoint Capital's largest Q4 2024 buy was Xenon Pharmaceuticals: 375,845 shares worth $14.7M.
- Stempoint Capital added most to Syndax Pharmaceuticals in Q4 2024, an estimated $19.5M increase.
- Stempoint Capital's biggest Q4 2024 reduction was Arcutis Biotherapeutics, cutting an estimated $14M.
- Stempoint Capital fully exited Amicus Therapeutics in Q4 2024, selling an estimated $15.8M.
- Stempoint Capital's ten largest holdings make up 51% of its $401M portfolio in Q4 2024.
- Stempoint Capital opened 26 new positions and closed 26 in Q4 2024.
- Stempoint Capital's portfolio value rose 20% quarter-over-quarter to $401M.
Based on Stempoint Capital's 13F filing for Q4 2024, filed 14 Feb 2025.